MENU
ARGX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

ARGX stock forecast, quote, news & analysis

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
ARGX
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for ARGX with price predictions
Oct 09, 2026

Momentum Indicator for ARGX turns negative, indicating new downward trend

ARGX saw its Momentum Indicator move below the 0 level on September 04, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 55 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ARGX turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 30 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.

ARGX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ARGX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

The Aroon Indicator for ARGX entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in 219 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

ARGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 22 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. ARGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.225) is normal, around the industry mean (26.780). P/E Ratio (37.045) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (1.189) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (12.330) is also within normal values, averaging (438.009).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 133.74B. VRTX holds the highest valuation in this group at 133.74B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was -4%. PDSB experienced the highest price growth at 84%, while CRBU experienced the biggest fall at -62%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -0%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
ARGX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of antibody-based medicines

Industry Biotechnology

Industry
Pharmaceuticals Other
Address
Laarderhoogtweg 25
Phone
+31 107038441
Employees
3522
Web
https://www.argenx.com
Momentum Indicator for ARGX turns negative, indicating new downward trend